CREBBP cooperates with the cell cycle machinery to attenuate chidamide sensitivity in relapsed/refractory diffuse large B-cell lymphoma

• Published in: Cancer letters Vol. 521; pp. 268 - 280
• Main Authors: Sun, Yichen, Gao, Yan, Chen, Jianfeng, Huang, Ling, Deng, Peng, Chen, Jinghong, Chai, Kelila Xin Ye, Hong, Jing Han, Chan, Jason Yongsheng, He, Haixia, Wang, Yali, Cheah, Daryl, Lim, Jing Quan, Chia, Burton Kuan Hui, Huang, Dachuan, Liu, Lizhen, Liu, Shini, Wang, Xiaoxiao, Teng, Yan, Pang, Diwen, Grigoropoulos, Nicholas Francis, Teh, Bin Tean, Yu, Qiang, Lim, Soon Thye, Li, Wenyu, Ong, Choon Kiat, Huang, Huiqiang, Tan, Jing
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier B.V 28.11.2021; Elsevier Limited
• Subjects: Antitumor activity; B-cell lymphoma; Biomarkers; Cancer therapies; Cell cycle; Cell growth; Chidamide; Clinical trials; CREBBP; DLBCL; Drug screening; Epigenetics; Experiments; Histone acetyltransferase; Histone deacetylase; Lymphocytes B; Lymphoma; Mutation; Patients; Plasmids; Resistance; Software; Resistance; DLBCL; CREBBP; Chidamide; Cell cycle

Diffuse large B-cell lymphoma (DLBCL) exhibits frequent inactivating mutations of the histone acetyltransferase CREBBP, highlighting the attractiveness of targeting CREBBP deficiency as a therapeutic strategy. In this study, we demonstrate that chidamide, a novel histone deacetylase (HDAC) inhibitor...